

# CROI 2008 Poster Sessions

Monday, February 4	
7 am-7 pm	Poster Halls open 7 am to 7 pm; all posters will be available for viewing for the duration of the conference.
1-4 pm	Poster Sessions
Hall D	<ul style="list-style-type: none"> <li><b>46.</b> Cellular Co-factors</li> <li><b>47.</b> Cellular Restrictions</li> <li><b>48.</b> Viral Accessory Genes</li> <li><b>57.</b> Factors Impacting Disease Progression</li> <li><b>58.</b> Factors Impacting Viral Replication <i>in vivo</i></li> <li><b>59.</b> Studies on Viral Evolution <i>in vivo</i></li> <li><b>67.</b> Therapy and CNS Infection</li> <li><b>68.</b> Clinical Developments in Neuropathogenesis</li> <li><b>73.</b> Studies on T Cell Responses in Viral Infection</li> <li><b>74.</b> Studies on Cytokines and HIV Infection</li> </ul>
Hall A	<ul style="list-style-type: none"> <li><b>84.</b> Molecular Epidemiology: The Americas</li> <li><b>85.</b> Molecular Epidemiology: Europe</li> <li><b>86.</b> Molecular Epidemiology: Africa and Asia</li> <li><b>87.</b> Epidemiology and Transmission in Adult Populations</li> <li><b>91.</b> Novel PrEP Agents and Evaluation Strategies</li> <li><b>95.</b> Pharmacokinetics and Children</li> <li><b>96.</b> Response to and Efficacy of ART in Children</li> <li><b>97.</b> Resistance after First-line Failure in Children</li> <li><b>105.</b> Antiretroviral Pharmacokinetics during Pregnancy</li> <li><b>106.</b> Resistance Associated with ART for PMTCT</li> <li><b>112.</b> Health Outcomes in Women</li> <li><b>113.</b> Infertility in HIV-infected Women</li> <li><b>116.</b> Acute HIV/SIV Infection: Characterization of Transmitted Viruses</li> <li><b>117.</b> Acute HIV/SIV Infection: Immune Responses</li> <li><b>118.</b> Acute HIV Infection: Treatment</li> <li><b>119.</b> Acute HIV Infection: Recognition and Correlates of Transmission</li> </ul>
Hall B	<ul style="list-style-type: none"> <li><b>127.</b> ART: Treatment-naïve Patients</li> <li><b>128.</b> ART: Treatment-experienced Patients</li> <li><b>131.</b> Treatment Outcomes in Scale-up Programs</li> <li><b>135.</b> New Mechanisms of HIV-1 Drug Resistance</li> <li><b>142.</b> Viral Rebound and Emergence of Drug Resistance</li> <li><b>143.</b> HIV-1 Drug Resistance after First-line Therapy</li> <li><b>144.</b> Changing Prevalence of HIV-1 Drug Resistance</li> <li><b>145.</b> Impact of Subtype on HIV-1 Drug Resistance</li> <li><b>146.</b> Simplified Diagnostics for Resource-limited Settings</li> <li><b>147.</b> Evaluation of Serodiagnostic Assays</li> <li><b>148.</b> HLA Testing: Refinements and Cost-effectiveness</li> <li><b>152.</b> Dyslipidemia: Role of ART and Interventions for Management</li> <li><b>153.</b> Lipoatrophy/Lipohypertrophy: Predictors and Interventions</li> <li><b>154.</b> Atherosclerosis, Cardiovascular Risk and HIV Infection</li> <li><b>169.</b> Hepatitis B Co-infection</li> <li><b>170.</b> Hepatitis C Co-infection: Cellular Immune Responses and Pathogenesis</li> <li><b>171.</b> Hepatitis C Co-infection: Fibrosis</li> </ul>

# CROI 2008 Poster Sessions

Tuesday, February 5	
7 am-7 pm	<i>Poster Halls open 7 am to 7 pm; all posters will be available for viewing for the duration of the conference.</i>
1-4 pm	Poster Sessions
Hall D	<ul style="list-style-type: none"> <li><b>49.</b> New Insights into APOBEC Proteins</li> <li><b>50.</b> Viral Replication Cycle: Molecular Studies</li> <li><b>51.</b> Viral Envelope: Tropism and Co-receptor Studies</li> <li><b>52.</b> Viral Fitness, Evolution and Recombination</li> <li><b>60.</b> CTL Studies and Consequences of Immune Escape</li> <li><b>61.</b> Factors Influencing CD4 Counts</li> <li><b>62.</b> HIV Superinfection and Viral Co-infection</li> <li><b>69.</b> Virologic Parameters in NeuroAIDS</li> <li><b>70.</b> Studies into Mechanisms of HIV Neuropathogenesis</li> <li><b>75.</b> Immune Activation and Lymphocyte Function</li> <li><b>76.</b> Studies on Regulatory T Cells</li> <li><b>77.</b> Immune Responses and Control of Viremia</li> </ul>
Hall A	<ul style="list-style-type: none"> <li><b>88.</b> New Approaches to HIV Testing</li> <li><b>92.</b> HIV-1 Prevention for Positives</li> <li><b>93.</b> Modeling the Cost-effectiveness and Impact of PrEP on Resistance</li> <li><b>98.</b> Complications, Neurodevelopment and ART-related Toxicities in Children</li> <li><b>99.</b> Mycobacterial Disease in Children</li> <li><b>100.</b> Prevention, Identification and Treatment of at-Risk and HIV-infected Adolescents</li> <li><b>107.</b> Maternal ART and Feeding Practices: Impact on Infant Outcomes</li> <li><b>108.</b> Infant Feeding, PMTCT and Infant Outcome</li> <li><b>109.</b> Properties of Breast Milk</li> <li><b>114.</b> Influence of Gender on HIV Replication and Viremia</li> <li><b>115.</b> HIV Replication, Immune Activation, HIV-2 Co-infection, and Genital Shedding in Women</li> <li><b>123.</b> ART: Novel Approaches I</li> <li><b>124.</b> ART: Novel Approaches II</li> <li><b>125.</b> Clinical Pharmacology of Reverse Transcriptase Inhibitors</li> <li><b>126.</b> Clinical Pharmacology of Protease Inhibitors</li> </ul>
Hall B	<ul style="list-style-type: none"> <li><b>132.</b> Switching Therapy/Treatment Failure in Scale-up Programs</li> <li><b>136.</b> Resistance to New Antiretrovirals</li> <li><b>137.</b> Emerging Patterns of Resistance to New Antiretrovirals</li> <li><b>138.</b> Minor Drug-resistant Variants: Detection and Clinical Significance</li> <li><b>149.</b> Impact of Subtype on HIV Quantification</li> <li><b>150.</b> New Diagnostic and Monitoring Tools</li> <li><b>155.</b> Hepatic Complications</li> <li><b>156.</b> Markers of Inflammation, Immunodeficiency and Complications</li> <li><b>157.</b> Changes in Bone Mineral Density</li> <li><b>158.</b> Renal Disease</li> <li><b>172.</b> Hepatitis C Co-infection: Markers, Outcome and Effect of ART</li> <li><b>173.</b> Hepatitis C Co-infection: Treatment</li> <li><b>174.</b> Hepatitis Co-infection: Cardiovascular and Malignancy Association</li> </ul>

# CROI 2008 Poster Sessions

Wednesday, February 6	
7 am-6 pm	<i>Poster Halls open 7 am to 6 pm; all posters will be available for viewing for the duration of the conference.</i>
1-4 pm	Poster Sessions
Hall D	<ul style="list-style-type: none"> <li><b>53.</b> HIV-1 Macrophage Studies</li> <li><b>54.</b> Co-infection: Virus/Virus Interactions</li> <li><b>55.</b> Viral Reservoirs</li> <li><b>56.</b> Viral Transmission: Molecular Studies</li> <li><b>63.</b> Studies on Elite Controllers and Exposed Uninfected</li> <li><b>64.</b> Studies of Non-progressive Infection</li> <li><b>65.</b> Lymphocyte Depletion in the Gut</li> <li><b>66.</b> Monocyte/Macrophage Studies</li> <li><b>71.</b> Co-infection with HCV</li> <li><b>72.</b> PML and JC Virus</li> <li><b>78.</b> B Cell and Immunoglobulin Studies</li> <li><b>79.</b> Studies on NK and Plasmacytoid Dendritic Cells</li> <li><b>80.</b> HIV Vaccines: Induction of Neutralizing Antibodies and Responses</li> <li><b>81.</b> HIV Vaccines: Induction of Cellular Immune Responses</li> <li><b>82.</b> HIV Vaccines: Novel Viral Vectors</li> <li><b>83.</b> HIV Vaccines: Clinical Trials</li> </ul>
Hall A	<ul style="list-style-type: none"> <li><b>89.</b> Expanding HIV Testing</li> <li><b>90.</b> Behavioral Risk in HIV Infection</li> <li><b>94.</b> Preclinical and Clinical Studies of Topical and Oral PrEP</li> <li><b>101.</b> Special Considerations in Laboratory Studies for Children</li> <li><b>102.</b> Transmission and Diagnosis of HIV Infection in Infants and Children</li> <li><b>103.</b> Immune Response in Children</li> <li><b>104.</b> Viral and Host Factors Associated with Pediatric Disease Progression</li> <li><b>110.</b> Risk, Timing and Viral Genetics of MTCT</li> <li><b>111.</b> Co-infections during Pregnancy</li> <li><b>120.</b> Immune-Based Therapies: Cytokines</li> <li><b>121.</b> Immune-Based Therapies: Therapeutic Vaccines</li> <li><b>122.</b> Immune-Based Therapies: Novel Approaches</li> </ul>
Hall B	<ul style="list-style-type: none"> <li><b>129.</b> ART: Adherence</li> <li><b>130.</b> HIV Care in Different Settings</li> <li><b>133.</b> Risk Factors for Lost-to-Follow-up in Resource-limited Settings</li> <li><b>134.</b> Complications in Resource-limited Settings</li> <li><b>139.</b> New Resistance Technologies</li> <li><b>140.</b> HIV-1 Drug Resistance: Genital Shedding and Recombination</li> <li><b>141.</b> HIV-2 Drug Resistance</li> <li><b>151.</b> Diagnosis and Monitoring Using Dried Specimens</li> <li><b>159.</b> Impact on Cardiac Function</li> <li><b>160.</b> Hypersensitivity Reactions: Other Drug Toxicities</li> <li><b>161.</b> <i>in vitro</i> and Animal Studies of Metabolic Toxicity</li> <li><b>162.</b> ART Toxicity in Resource-limited Settings</li> <li><b>163.</b> TB Screening and Diagnostics</li> <li><b>164.</b> HIV/TB Co-infection</li> <li><b>165.</b> TB-associated Immune Reconstitution Inflammatory Syndrome</li> <li><b>166.</b> Cryptococcal and Herpesvirus Infections</li> <li><b>167.</b> Infectious Complications</li> <li><b>168.</b> Malignancies</li> </ul>